High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Daratumumab is a CD38‐targeted human monoclonal antibody with direct anti‐myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated with daratumumab revealed cytotoxic T‐cell expansion and reduction of immune‐suppressive populations, sug...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, Homer C., Stevenaert, Frederik, Krejcik, Jakub, Van der Borght, Koen, Smets, Tina, Bald, Jaime, Abraham, Yann, Ceulemans, Hugo, Chiu, Christopher, Vanhoof, Greet, Usmani, Saad Z., Plesner, Torben, Lonial, Sagar, Nijhof, Inger, Lokhorst, Henk M., Mutis, Tuna, van de Donk, Niels W.C.J., Sasser, Amy Kate, Casneuf, Tineke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590645/
https://www.ncbi.nlm.nih.gov/pubmed/30536810
http://dx.doi.org/10.1002/cyto.a.23693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590645/
https://www.ncbi.nlm.nih.gov/pubmed/30536810
http://dx.doi.org/10.1002/cyto.a.23693

Ejemplares similares